Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: Effectiveness comparative study;Estudio comparativo de efectividad de los inhibidores del factor de necrosis tumoral alfa en la artritis reumatoide establecida

Medicina Clinica

Volumn 134, Issue 15, 2010, Pages 665-670

  Arenere Mendoza, Mercedes ^a   Manero Ruiz, Francisco Javier ^b   Carrera Lasfuentes, Patricia ^c   Navarro Aznárez, Herminia ^b   Pecondón Español, Ángela ^b   Rabanaque Hernández, María José ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Adalimumab; Disease Activity Score 28; Effectiveness; Etanercept; Health Assessment Questionnaire; Infliximab; Rheumatoid arthritis; Tumour necrosis factor alpha antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SPAIN; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952240142     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.09.050     Document Type: Article

References (30)

1. L. Absolo, E. Jdez, M.A. Descalzo, I. Gonzlez-lvaro, J.A. Jover, L. Carmona EMECAR Study Group Cancer in rheumatoid arthritis: Occurrence, mortality, and associated factors in a South European population Semin Arthritis Rheum 37 2008 388 397
2. I. Del Rincn, K. Williams, M. Stern, G. Freeman, and A. Escalante High incidence of cardiovascular events in a rheumatoid athritis cohort not explained by traditional cardiac risk factors Arthritis Rheum 44 2001 2737 2745
3. Sociedad Espaola de Farmacia Hospitalaria. Principios bsicos de la artritis reumatoide: diferencias entre AR precoz y AR establecida. En: Curso de terapias biolgicas en reumatologa. Madrid 2005
4. K.G. Saag, G.G. Teng, N.M. Patkar, J. Anuntiyo, C. Finney, and J.R. Curtis American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 2008 764 784
5. D. Snchez, J.L. Callejas, and N. Ortego Uso de los frmacos antagonistas del factor de necrosis tumoral en las enfermedades autoinmunes: situacin actual Med Clin (Barc) 131 2008 471 477
6. Y.F. Chen, P. Jobanputra, P. Barton, S. Jowett, S. Bryan, and W. Clark A systematic review of effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and economic evaluation of their cost-effectiveness Health Technol Assess 10 2006 1 229
7. P.E. Lipsky, D.M.F.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 2000 1594 1602
8. F.C. Breedveld, P. Emery, E. Keystone, K. Patel, J.R. Kalden, and E.W. St Clair Infliximab in active early rheumatoid arthritis Ann Rheum Dis 63 2004 149 155
9. E.W. St Clair, D.M.F.M. van der Heijde, J.S. Smolen, N.M. Raviner, J.M. Buthon, and P. Emery Combination of infliximab and methotrexate therapy for early rheumatoid arthritis Arthritis Rheum 50 2004 3432 3443
10. R. Westhovens, D. Yocum, J. Han, A. Berman, I. Strusbergg, and P. Geusens The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities Arthritis Rheum 54 2006 1075 1086
11. J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, and E.C. Keystone A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 2000 1586 1593
12. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 363 2004 675 681
13. L.W. Moreland, M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, and K.J. Bulpitt Etanercept therapy in rheumatoid arthritis Ann Intern Med 130 1999 478 486
14. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, and R.I. Fox A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253 259
15. M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, and C.A. Birbara Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate Arthritis Rheum 48 2003 35 45
16. M.E. Weinblatt, E.C. Keystone, D.E. Furst, A.F. Kavanaugh, E.K. Chartash, and O.G. Segurado Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study Ann Rheum Dis 65 2006 753 759
17. F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, and R. Van Vollenhoven A multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
18. D.E. Furst, M.H. Schiff, R.M. Fleischmann, V. Strand, C.A. Birbara, and D. Compagnone Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid arthritis) J Rheumatol 30 2004 2563 2571
19. W. Kievit, J. Fransen, A.J.M. Oerlemans, H.H. Kuper, M.A.F.J. van de Laar, and D.J.R.A.M. de Rooij The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice Ann Rheum Dis 66 2007 1473 1478
20. V. Rodrguez-Valverde, R. Cliz, J.M. lvaro-Gracia, J.L. Marenco, J. Mulero, and J. Tornero III Actualizacin del Consenso de la Sociedad Espaola de Reumatologa sobre terapia biolgica en la artritis reumatoide Reumatol Clin 2 2006 52 59
21. A. Balsa, L. Carmona, I. Gnzalez-lvaro, M.A. Belmonte, X. Tena, and R. Sanmart Value of disease activity score 28 (DAS 28) and DAS 28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis J Rheumatol 31 2004 40 46
22. A.M. Van Gestel, C.J. Haagsma, and P.L. van Riel Validation of rheumatoid arthritis improvement criteria that include simplified joint counts Arthritis Rheum 41 1998 1845 1850
23. J. Carbonell, X. Bada grupo EXPRESAR Expectativas, preferencias y satisfaccin de los pacientes con artritis reumatoide en tratamiento con infliximab Med Clin (Barc) 131 2008 493 499
24. A. Balsa, V. Villaverde, and E. Martn-Mola Índices de actividad y mejora de la artritis reumatoide Rev Esp Reumatol Suplementos 1 2002 4 8
25. M.A. Descalzo Comit cientfico de BIOBADASER y grupo de estudio de BIOBADASER Registro espaol de acontecimientos adversos de terapias biolgicas en enfermedades reumticas (BIOBADASER): informe de situacin, 26 de enero de 2006 Reumatol Clin 3 2007 4 20
26. G. Gartlehner, R.A. Hansen, B.L. Jones, P. Thieda, and K.N. Lohr The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and meta-analysis J Rheumatol 33 2006 2398 2408
27. M.C. Hochberg, J.K. Tracy, M. Hawkins-Holt, and R.H. Flores Comparison of efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis Ann Rheum Dis 62 2003 13 16
28. A. Fernndez-Nebro, M.V. Irigoyen, I. Urea, M.A. Belmonte-Lpez, C. Coret, and F.G. Jimnez-Nez Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis J Rheumatol 34 2007 2334 2342
29. W. Kievit, E.M. Adang, J. Fransen, H.H. Kuper, M.A.F.J. van de Laar, and T.L. Jansen The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data Ann Rheum Dis 67 2008 1229 1234
30. I. Gonzlez Tratamiento de inicio en la artritis reumatoide con tratamientos biolgicos. Postura en contra Reumatol Clin 2009 10.1016/j.reuma.2008.11.008